ClinConnect ClinConnect Logo
Search / Trial NCT01229813

Avastin and Chemotherapy Followed by a KRAS Stratified Randomization to Maintenance Treatment for First Line Treatment of Metastatic Colorectal Cancer.

Launched by LUND UNIVERSITY HOSPITAL · Oct 27, 2010

Trial Information

Current as of July 06, 2025

Completed

Keywords

Untreated First Line Chemotherapy Maintenance Treatment Kras Wt Kras Mutated Anti Angiogenetic Treatment Metronomic Capecitabine Bevacizumab Erlotinib Translational Research

ClinConnect Summary

No description provided

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Untreated metastatic colorectal carcinoma
  • Age 18 yrs or over
  • Measurable disease according to Response Evaluation Criteria in solid Tumors (RECIST criteria)
  • ECOG performance status 0 or 1
  • Life expectancy more than 3 months
  • Adequate haematological, renal and liver function
  • Tumor tissue available for determination of KRAS mutational status
  • Blood sample and paraffin embedded tumor tissue for translational research
  • Exclusion Criteria:
  • Adjuvant therapy within 6 months
  • CNS metastases
  • Clinically significant atherosclerotic vascular disease

About Lund University Hospital

Lund University Hospital, affiliated with Lund University in Sweden, is a leading institution in medical research and clinical trials. Renowned for its commitment to advancing healthcare through innovative research, the hospital integrates clinical practice with academic excellence. As a sponsor of clinical trials, Lund University Hospital focuses on a wide range of therapeutic areas, striving to improve patient outcomes by rigorously evaluating new treatments and interventions. With a multidisciplinary team of expert researchers and clinicians, the hospital emphasizes ethical standards, patient safety, and scientific integrity in all its studies, contributing significantly to the global medical community.

Locations

Stockholm, , Sweden

Sundsvall, , Sweden

Karlstad, , Sweden

Odense, , Denmark

Jönköping, , Sweden

Kalmar, , Sweden

Linköping, , Sweden

Lund, , Sweden

Umeå, , Sweden

Uppsala, , Sweden

Västerås, , Sweden

Växjö, , Sweden

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials